VivoSeq
Oncology

Merkel Cell Carcinoma

40

Pipeline Programs↗

19

Active Trials↗

23

Companies Involved↗

Merkel Cell Carcinoma is a moderately active landscape with 40 programs across 23 companies. The most active players are Novartis, Fujifilm Pharmaceuticals U.S.A., Inc., Immunomic Therapeutics, Inc.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

19/100

Mech. Concentration

14/100

Completion Rate

55/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1F

Fujifilm Pharmaceuticals U.S.A., Inc.

1 program

Phase 1I

Immunomic Therapeutics, Inc.

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1Merck & Co. logo

Merck & Co.

2 programs

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

4 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

63%

Small molecule

22 of 35 classified programs — the dominant modality here.

37%ALL OTHERSMonoclonal antibody823%Peptide26%Protein / enzyme13%RNA therapy13%Gene therapy13%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 98% of 46 pipeline programs.

Analysis

Trial Status

43

clinical trials

Completed12 · 28%
Active, not recruiting9 · 21%
Recruiting8 · 19%
Terminated7 · 16%
Withdrawn3 · 7%
Not yet recruiting2 · 5%
Other2 · 5%

Clinical Trials

Trial Activity

43 trials

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Recruiting·TTuHURA Biosciences, Inc.·Phase 2/3·NCT06947928·118 enrolled
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Recruiting·MMelanoma Institute Australia·Phase 2·NCT06151236·20 enrolled
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05100095·52 enrolled
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Recruiting·—·Phase 2·NCT05496036·15 enrolled
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Recruiting·TTuHURA Biosciences, Inc.·Phase 1·NCT06940440·9 enrolled
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
Recruiting·MMelanoma and Skin Cancer Trials Limited·Phase 1/2·NCT04261855·19 enrolled
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT04975152·36 enrolled
Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
Recruiting·OOhio State University Comprehensive Cancer Center·N/A·NCT07215988·70 enrolled
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04792073·18 enrolled
Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03712605·280 enrolled
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Active, not recruiting·MMelanoma and Skin Cancer Trials Limited·Phase 2·NCT04291885·122 enrolled
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03304639·9 enrolled
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Active, not recruiting·FFujifilm Pharmaceuticals U.S.A., Inc.·Phase 1·NCT04047251·96 enrolled
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Active, not recruiting·UUniversity of Washington·Phase 2·NCT06056895·12 enrolled
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
Active, not recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT05594290·36 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)